Rimegepant - Biohaven Pharmaceutical Holding Company

Drug Profile

Rimegepant - Biohaven Pharmaceutical Holding Company

Alternative Names: BHV-3000; BMS-927711; Rimegepant sulfate

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Biohaven Pharmaceutical Holding Company; Bristol-Myers Squibb
  • Class 2 ring heterocyclic compounds; Antimigraines; Cycloheptanes; Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 29 Nov 2017 Biohaven Pharmaceuticals Holding Company completes a phase IIb trial in Migraine in USA (NCT01430442)
  • 27 Nov 2017 Biohaven Pharmaceutical Holding Company completes enrolment in its phase III BHV3000-302 trial for Migraine in USA (PO) (NCT03237845)
  • 20 Nov 2017 Biohaven Pharmaceutical Holding Company receives agreement from US FDA on initial paediatric study plan (iPSP) for rimegepant
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top